This editorial refers to 'Visit-to-visit stabilization, namely a change in plaque composition reducing its vulnerability, has also been proposed as the potential underlying pathophysiological mechanism. 3-5 However, pivotal randomized clinical trials (RCTs) using IVUS to ascertain the effects of novel therapies on plaque progression paid little attention to plaque composition.
Intravascular ultrasound (IVUS) provides accurate and reproducible measurements of coronary atheroma burden. [1] [2] [3] [4] [5] Classical serial IVUS studies in patients with coronary artery disease (CAD) demonstrated that high-intensity therapy with lipid-lowering drugs slows progression or induces regression of coronary plaques. [3] [4] [5] Overall, the amount of plaque regression is limited and seems insufficient to explain the striking clinical benefit demonstrated by intense lipidlowering therapy. The pleiotropic effects of statins have been implicated to explain this apparent paradox. [3] [4] [5] In addition, plaque stabilization, namely a change in plaque composition reducing its vulnerability, has also been proposed as the potential underlying pathophysiological mechanism. [3] [4] [5] However, pivotal randomized clinical trials (RCTs) using IVUS to ascertain the effects of novel therapies on plaque progression paid little attention to plaque composition. [3] [4] [5] Moreover, the influence of plaque changes on lumen changes has been poorly examined. Remodelling phenomena are highly prevalent and explain the frequent dissociation between plaque and luminal changes. [1] [2] [3] [4] [5] Optical coherence tomography has 10 times the spatial resolution of IVUS and is superior to identify surrogate features of plaque vulnerability. 6 However, its penetration in the vessel wall is rather shallow, limiting its ability to visualize the entire plaque. 6 At the other extreme of the diagnostic spectrum, coronary computed tomography angiography nicely demonstrates coronary plaque. This noninvasive technique holds potential to assess changes in plaque burden, but, due to its limited spatial resolution and lack of clinical validation, has not been used to monitor CAD progression. Therefore, currently IVUS remains the 'gold standard' for volumetric plaque quantification. Progression studies have focused on either absolute changes in total atheroma volume or changes in percent atheroma volume (DPAV) (the proportion of the vessel occupied by atherosclerotic plaque). [3] [4] [5] These have been used as surrogate endpoints in trials assessing novel anti-atherosclerotic drugs in order to reduce the required number of patients and follow-up time. Notably, both baseline plaque burden and DPAV have been associated with cardiovascular events.
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Present study
In their study published in this issue of the journal, Clark et al. 7 performed a post-hoc, patient-level analysis of nine RCTs involving a total of 4976 patients with established CAD who underwent serial IVUS studies to assess the efficacy of several pharmacological regimens on CAD progression. The main outcome measure was DPAV, whereas clinical outcomes were secondary endpoints. Overall, the PAV of the total population remained unchanged during the study. The influence of visit-to-visit atherogenic lipid variability, including LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), non-HDL-C, total cholesterol (TC)/HDL-C, and apolipoprotein B (ApoB), on disease progression was analysed. Variability of these lipid parameters during 2 years was assessed using the intra-individual standard deviation. Interestingly, lipoprotein variability [changes in LDL-C, non-HDL-C, TC/HDL-C, and ApoB (all P = 0.01)] was associated with DPAV. Final lipoprotein levels also showed a strong association with DPAV. Importantly, significant stepwise relationships were found between increasing quartiles of atherogenic lipoprotein variability and cardiovascular events. The authors should be commended for this elegant analysis demonstrating, for the first time, an association between variability of atherogenic lipoproteins and both DPAV and clinical outcomes. 7 In spite of adjusting for potential confounders (including achieved LDL-C levels), greater visit-to-visit variability in atherogenic lipoprotein levels was independently associated with atheroma progression and adverse cardiovascular outcomes. These findings would suggest the importance of achieving consistently low lipoprotein levels to halt coronary plaque progression and improve prognosis in patients with CAD (Take home figure) . Although proving causality remains elusive, the results of this pooled analysis would suggest that lipoprotein variability is directly associated with a pro-atherosclerotic process leading to increased cardiovascular events. Accordingly, discussing some methodological issues would be of major clinical interest. First, the RCTs included in this analysis assessed the effect not only of different statins, but also of anti-hypertensive medications, cholesteryl-ester transfer protein inhibitors, endocannibanoid receptor antagonists, and peroxisome proliferator-activated receptor-c agonists. Guideline-recommended optimal medical therapy was used in the control arms. Notably, the main outcome measures were adjusted by the potential influence of the specific trial and baseline PAV. Although unmeasured residual confounders may affect the results of this pooled analysis of heterogeneous trials, consistently, robust results were found in the different regression models and sensitivity analyses performed.
Secondly, all these IVUS studies were centrally analysed in a core lab with accredited reproducibility. Indeed, during the last decade, this core lab at the Cleveland Clinic has been a reference in the field, setting the standards for IVUS acquisition and measurements in CAD progression studies. [3] [4] [5] Thirdly, only vessels with mild angiographic disease were analysed. These segments may not be representative of the sites prone to generate acute ischaemic events. Whether current findings may be extrapolated to those occurring at the worst segment or in patients with significant lesions remains unsettled. The study selected PAV rather than total atheroma volume because the former demonstrated a better accuracy to predict clinical events. 5 However, PAV may be affected by vessel remodelling. Moreover, although this methodology nicely evaluates overall changes in plaque burden, it fails to identify significant 'focal' plaque accumulation that also may have clinical consequences.
Likewise, patients with severe vessel calcification (preventing identification of the external elastic lamina) were excluded. [3] [4] [5] Finally, revascularization was the main driver of clinical events, yet whether these events actually related to the index imaged segment remains unknown. Fourthly, in this analysis standard deviation and average successive variability of lipoprotein levels showed a strong statistical correlation. This is reassuring regarding the value of these previously validated outcome measures. However, standardized definitions of lipid variability should be devised to allow targeting for variability in prospective studies powered for clinical outcomes.
Fifthly, serial imaging ranged from 18 to 24 months. The limitation of this reduced time frame, that only provides a snapshot of plaque changes, should be acknowledged considering the long natural history of CAD. Besides, plaque progression may not follow a linear temporal pattern and currently its course remains unpredictable.
Finally, the levels of LDL-C achieved in the overall population were 83 ± 28 mg/dL. This could be criticized considering current standards in secondary prevention. It is unknown whether these findings could be generalized to patients receiving more aggressive lipidlowering therapies. In the population achieving on-treatment LDL-C levels <70 mg/dL, there was not a significant association between LDL-C variability and DPAV. Alternatively, as compliance rates are very high in RCTs, these results may not be extrapolated to everyday clinical practice, where variability and final LDL-C levels are expected to be less satisfactory.
Previous studies
Fluctuations in biological variables have been classically associated with prognosis. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] A lower heart rate variability predicts poorer In patients with stable CAD, visit-to-visit LDL-C variability predicts an increased risk of cardiovascular events. In a post-hoc analysis of the TNT (Treatment to New Targets) trial, where 10 000 patients with known CAD and LDL-C <130 mg/dL were randomized to 80 vs. 10 mg/day atorvastatin, Bangalore et al. 10 demonstrated that visitto-visit LDL-C variability was a strong predictor of coronary events, even after adjusting for treatment effect, statin adherence, and achieved LDL-C levels. Interestingly, LDL-C variability was lower in patients on high-dose atorvastatin. A subsequent analysis from this trial found that not only LDL-C variability but also variability in HDL-C and in triglycerides were independent predictors of cardiovascular events. 11 In another post-hoc study, 12 including 8600 stable patients with a previous history of myocardial infarction, variabilities in both LDL-C and blood pressure were independent predictors of cardiovascular events. Again, LDL-C variability was lower in patients receiving high-dose statins. Similar findings were subsequently reproduced in patients with acute coronary syndromes. In a single-centre study including 130 patients with acute myocardial infarction, Boey et al. 13 found an independent association between visit-to-visit LDL-C and HDL-C variability and 5-year rate of adverse cardiac events. Nationwide epidemiological studies provide complementary evidence from the general population. 14, 15 In a huge sample of 3650 000 Korean subjects followed for 8.3 years, a linear association was found between TC variability and adverse cardiovascular events that persisted after adjusting for lipid-lowering treatment and cholesterol levels. 14 TC variability also predicted development of end-stage renal disease. 15 This is interesting as intense statin therapy reduces the risk of kidney failure. Similar findings have been seen in other vascular territories. [16] [17] [18] In elderly patients, higher visit-to-visit LDL-C variability was associated with lower cognitive performance, lower cerebral blood flow, and greater white matter hyperintensity load. 16, 17 Until now, however, there was no evidence linking this biological marker with subclinical atherosclerosis. A recent observational study from Japan in diabetic patients suggested that visit-to-visit LDL-C variability was an independent predictor of carotid intima-media thickness. 18 This association was independent of lipid values and variability in HbA 1c and blood pressure. In most of these studies, the association between lipoprotein variability and clinical outcomes was independent of the effects of statin therapy. [10] [11] [12] [13] [14] [15] [16] [17] [18] Accordingly, it was suggested that cholesterol variability might be a marker of a high residual risk.
Causes and implications of atherogenic lipoprotein variability
A host of factors account for LDL-C variability. Lipid variability may be simply a marker of associated pathological conditions or general frailty explaining poorer clinical outcomes. [10] [11] [12] [13] [14] [15] [16] [17] [18] Accordingly, lipid variability may be just an epiphenomenon and, therefore, should not be considered a valid therapeutic target. In the clinical setting, nonadherence to lipid-lowering drugs may explain not only lipid variability but also poor compliance with other medications with proven beneficial clinical effects. [10] [11] [12] [13] [14] [15] [16] [17] [18] Conversely, lipid variability may represent a loss of the physiological homeostasis and represent a true risk factor. Some biologically plausible mechanisms might be implicated. [10] [11] [12] [13] [14] [15] [16] [17] [18] Genetic polymorphisms regulating the LDL-C receptor may influence LDL-C variability. LDL-C variability might also be associated with variability in the beneficial pleiotropic effects of statins, including the anti-inflammatory effects potentially affecting fibrous cap stability. LDL-C variability may impair endothelial function. Last, but not least, the lipid efflux from the lipid core of plaques, affecting their vulnerability, may be influenced by LDL-C variability. [10] [11] [12] [13] [14] [15] [16] [17] [18] Drastic lipid lowering with the new PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors is emerging as an attractive therapeutic strategy for selected patients with high residual risk. 19 However, some dosing schedules have been associated with significant fluctuations of LDL-C. Whether LDL-C variability may be a concern in patients achieving very low LDL-C levels requires additional investigation, although in the present study no effects on plaque progression occurred in patients achieving LDL-C levels <70 mg/dL. 7 
Final remarks
A growing body of evidence suggests that LDL-C variability has major clinical implications. [10] [11] [12] [13] [14] [15] [16] [17] [18] The present results extend the importance of cholesterol variability into a broad range of atherogenic lipoproteins. More importantly, the present study suggests a potential link between the variability of atherogenic lipoproteins and both plaque progression and long-term clinical outcomes. 7 Therefore, achieving stable reductions in atherogenic lipoproteins might emerge as a potential goal in secondary prevention. Significant variability in atherogenic lipids may identify high-risk individuals that might benefit from broader preventive strategies. The potential benefit of potent novel lipid-lowering agents in these high-risk patients deserves further research. 19 Furthermore, targeting for inflammation is also appealing in patients with a high residual risk. 20, 21 Statins prevent leucocyte recruitment at inflammatory foci, 21 and evidence points to inflammatory cytokines as key players in atheroma progression. Whether variability in plasma levels of pro-inflammatory cytokines also contribute to disease progression remains unknown. Future studies should examine whether reducing the variability in lipid parameters may help to decrease global cardiovascular risk. This information is required before LDL-C variability may be used to inform clinical practice.
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